News stories about OptiNose (NASDAQ:OPTN) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OptiNose earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.5977422601721 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have effected Accern’s scoring:

How to Become a New Pot Stock Millionaire

OptiNose (NASDAQ OPTN) opened at $19.50 on Friday. The company has a current ratio of 16.13, a quick ratio of 15.99 and a debt-to-equity ratio of 0.47. OptiNose has a 12-month low of $15.01 and a 12-month high of $21.50.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings results on Tuesday, March 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.18). research analysts predict that OptiNose will post -3 earnings per share for the current fiscal year.

A number of brokerages have recently issued reports on OPTN. Zacks Investment Research lowered OptiNose from a “hold” rating to a “sell” rating in a research report on Saturday, March 17th. Piper Jaffray Companies set a $28.00 target price on OptiNose and gave the company a “buy” rating in a research note on Monday, January 15th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. OptiNose presently has a consensus rating of “Buy” and an average price target of $29.25.

In other news, CEO Peter K. Miller purchased 5,054 shares of the business’s stock in a transaction on Friday, March 16th. The stock was purchased at an average price of $18.58 per share, with a total value of $93,903.32. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

WARNING: “OptiNose (OPTN) Earns Media Impact Rating of 0.12” was posted by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/optinose-optn-earns-media-impact-rating-of-0-12/1961157.html.

About OptiNose

OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.

Insider Buying and Selling by Quarter for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.